A new type of combined boxing therapy is expected to treat pancreatic cancer

Photo: DrZe'ev Ronai, a researcher at Sanford Burnham Prebys, said the treatment of pancreatic cancer is lagging behind because of the lack of effective treatments to attack the tumor tissue; in this study, we identified a potential combination of therapies that could be used to help fight malignant pancreatic cancer; and researchers are currently discussing how to use the new method in clinical evaluationpancreatic cancer is a deadly cancer that is often difficult to diagnose because symptoms of the disease, such as abdominal pain, yellowing of the skin and eyes, weight loss, etc., do not occur until the patient's disease is advancedLess than 10 percent of pancreatic cancer patients survive more than five years, and more than 56,000 Americans will be diagnosed with pancreatic cancer in 2019, according to the American Cancer Societystudy, researchers starved pancreatic tumors to death with a drug called L-Asparaginase, an amino acid needed for protein synthesis, using a drug called L-Asparaginase, an amino acid needed to synthesize a protein; The FDA currently approves L-mentomidase for the treatment of specific leukemias, while a second drug, called MEK inhibitor, is approved to treat skin cancers such as melanomaM.DEytan Ruppin notes that this study lays the foundation for clarifying the combination of tempoamide inhibitors and MAPK signal inhibitors to attack pancreatic tumors and inhibit their growth; It's clear that researchers can't find a single panacea for cancer, especially pancreatic cancer, but rather several drugs that address multiple weaknesses in cancer, and the findings offer a new strategy for treating pancreatic cancer;, the researchers also found that both treatments reduced the number of melanomas in mice, and that because of the current high clinical need for pancreatic cancer, later scientists needed to invest more in developing effective treatments for pancreatic canceroriginal origin:Pathria, G., Lee, J.S., Hasnis, Eet alTranslational reprogramming marks to asparagine restriction in cancerNat Cell Biol (2019) doi: 10.1038/s41556-019-0415-1